A Cross-Sectional Study on Side Effects of “Corbevax” Covid-19 Vaccine among 12- to 14-Year Age Group in a Tertiary Care Hospital in Meerut, Uttar Pradesh
Background: The first mass vaccination program for COVID-19 in India started on January 16, 2021. Initially, Covaxin and Covishield were used. Later, the Government of India has approved the usage of Corbevax, a Hyderabad-based biological E SARS-CoV-2 (COVID-19) vaccine among 12- to 14-year age grou...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Indian Journal of Community Medicine |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ijcm.ijcm_681_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087285091270656 |
|---|---|
| author | Chhaya Mittal Harimu Bargayary Mohit Saini |
| author_facet | Chhaya Mittal Harimu Bargayary Mohit Saini |
| author_sort | Chhaya Mittal |
| collection | DOAJ |
| description | Background:
The first mass vaccination program for COVID-19 in India started on January 16, 2021. Initially, Covaxin and Covishield were used. Later, the Government of India has approved the usage of Corbevax, a Hyderabad-based biological E SARS-CoV-2 (COVID-19) vaccine among 12- to 14-year age group from March 16, 2022. Corbevax vaccination was started in our hospital setting on March 19, 2022, for 12- to 14-year age group. Monitoring safety of any vaccine is of importance in a real-world setting. Limited study has been performed till date on side effects of Corbevax vaccine. Therefore, this study has been planned to assess the side effects after Corbevax vaccination among 12- to 14-year age group in a tertiary care hospital setting in Meerut district. To assess the side effects after Corbevax vaccination among 12- to 14-year age group in a tertiary care hospital setting in Meerut district. Tertiary care hospital setting and cross-sectional study design.
Methods and Material:
A cross-sectional study was conducted among 270 study participants. Sample size was calculated assuming 50% prevalence of side effects after vaccination. Study subjects were selected by using simple random sampling among the beneficiaries of a tertiary care center. Data were collected using a pretested semistructured questionnaire. Proportions, Chi-square test.
Results:
Of all the participants, 41.48% had developed side-effects with pain at site of injection being the most commonly reported symptom (64.29%), and about half among those affected had resolved spontaneously.
Conclusions:
The vaccine causes only mild symptoms and is safe for use in children. |
| format | Article |
| id | doaj-art-f4d16befaf43446a81bc868a74fdc010 |
| institution | Kabale University |
| issn | 0970-0218 1998-3581 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Community Medicine |
| spelling | doaj-art-f4d16befaf43446a81bc868a74fdc0102025-02-06T05:32:49ZengWolters Kluwer Medknow PublicationsIndian Journal of Community Medicine0970-02181998-35812025-01-0150123023310.4103/ijcm.ijcm_681_23A Cross-Sectional Study on Side Effects of “Corbevax” Covid-19 Vaccine among 12- to 14-Year Age Group in a Tertiary Care Hospital in Meerut, Uttar PradeshChhaya MittalHarimu BargayaryMohit SainiBackground: The first mass vaccination program for COVID-19 in India started on January 16, 2021. Initially, Covaxin and Covishield were used. Later, the Government of India has approved the usage of Corbevax, a Hyderabad-based biological E SARS-CoV-2 (COVID-19) vaccine among 12- to 14-year age group from March 16, 2022. Corbevax vaccination was started in our hospital setting on March 19, 2022, for 12- to 14-year age group. Monitoring safety of any vaccine is of importance in a real-world setting. Limited study has been performed till date on side effects of Corbevax vaccine. Therefore, this study has been planned to assess the side effects after Corbevax vaccination among 12- to 14-year age group in a tertiary care hospital setting in Meerut district. To assess the side effects after Corbevax vaccination among 12- to 14-year age group in a tertiary care hospital setting in Meerut district. Tertiary care hospital setting and cross-sectional study design. Methods and Material: A cross-sectional study was conducted among 270 study participants. Sample size was calculated assuming 50% prevalence of side effects after vaccination. Study subjects were selected by using simple random sampling among the beneficiaries of a tertiary care center. Data were collected using a pretested semistructured questionnaire. Proportions, Chi-square test. Results: Of all the participants, 41.48% had developed side-effects with pain at site of injection being the most commonly reported symptom (64.29%), and about half among those affected had resolved spontaneously. Conclusions: The vaccine causes only mild symptoms and is safe for use in children.https://journals.lww.com/10.4103/ijcm.ijcm_681_23aefiaesicorbevax vaccinecovid-19pandemicside effectsvaccination |
| spellingShingle | Chhaya Mittal Harimu Bargayary Mohit Saini A Cross-Sectional Study on Side Effects of “Corbevax” Covid-19 Vaccine among 12- to 14-Year Age Group in a Tertiary Care Hospital in Meerut, Uttar Pradesh Indian Journal of Community Medicine aefi aesi corbevax vaccine covid-19 pandemic side effects vaccination |
| title | A Cross-Sectional Study on Side Effects of “Corbevax” Covid-19 Vaccine among 12- to 14-Year Age Group in a Tertiary Care Hospital in Meerut, Uttar Pradesh |
| title_full | A Cross-Sectional Study on Side Effects of “Corbevax” Covid-19 Vaccine among 12- to 14-Year Age Group in a Tertiary Care Hospital in Meerut, Uttar Pradesh |
| title_fullStr | A Cross-Sectional Study on Side Effects of “Corbevax” Covid-19 Vaccine among 12- to 14-Year Age Group in a Tertiary Care Hospital in Meerut, Uttar Pradesh |
| title_full_unstemmed | A Cross-Sectional Study on Side Effects of “Corbevax” Covid-19 Vaccine among 12- to 14-Year Age Group in a Tertiary Care Hospital in Meerut, Uttar Pradesh |
| title_short | A Cross-Sectional Study on Side Effects of “Corbevax” Covid-19 Vaccine among 12- to 14-Year Age Group in a Tertiary Care Hospital in Meerut, Uttar Pradesh |
| title_sort | cross sectional study on side effects of corbevax covid 19 vaccine among 12 to 14 year age group in a tertiary care hospital in meerut uttar pradesh |
| topic | aefi aesi corbevax vaccine covid-19 pandemic side effects vaccination |
| url | https://journals.lww.com/10.4103/ijcm.ijcm_681_23 |
| work_keys_str_mv | AT chhayamittal acrosssectionalstudyonsideeffectsofcorbevaxcovid19vaccineamong12to14yearagegroupinatertiarycarehospitalinmeerututtarpradesh AT harimubargayary acrosssectionalstudyonsideeffectsofcorbevaxcovid19vaccineamong12to14yearagegroupinatertiarycarehospitalinmeerututtarpradesh AT mohitsaini acrosssectionalstudyonsideeffectsofcorbevaxcovid19vaccineamong12to14yearagegroupinatertiarycarehospitalinmeerututtarpradesh AT chhayamittal crosssectionalstudyonsideeffectsofcorbevaxcovid19vaccineamong12to14yearagegroupinatertiarycarehospitalinmeerututtarpradesh AT harimubargayary crosssectionalstudyonsideeffectsofcorbevaxcovid19vaccineamong12to14yearagegroupinatertiarycarehospitalinmeerututtarpradesh AT mohitsaini crosssectionalstudyonsideeffectsofcorbevaxcovid19vaccineamong12to14yearagegroupinatertiarycarehospitalinmeerututtarpradesh |